Fi­bro­Gen, fresh off da­ta ma­nip­u­la­tion scan­dal, touts win in can­cer pa­tients with­out re­veal­ing da­ta

Fi­bro­Gen’s lead drug has cleared an­oth­er mid-stage study. Or at least the biotech claims it has.

Fi­bro­Gen, a 28-year-old com­pa­ny whose stock col­lapsed this past year af­ter it re­vealed da­ta it had sub­mit­ted to the FDA was ma­nip­u­lat­ed, said Wednes­day that rox­adu­s­tat, its pill for ane­mia, suc­cess­ful­ly treat­ed can­cer pa­tients who suf­fered ane­mia as a side ef­fect of chemother­a­py.

The San Fran­cis­co biotech, though, re­vealed few de­tails about the 92-pa­tient study, ex­cept that it was “pos­i­tive.” The study’s pri­ma­ry end­point was the max­i­mum change in pa­tients’ he­mo­glo­bin lev­els with­out them un­der­go­ing a red blood cell trans­fu­sion, but Fi­bro­Gen didn’t say how much pa­tients’ lev­els changed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER